TRPV1 and cancer: Capsaicin, a well-studied nutraceutical compound [49,50,51,52], and its selective TRPV1 antagonist AMG9810, extensively used in preclinical models of pain, inflammation, and cancer [25,79], were both effective in modulating TRPV1 activity in OS cells while sparing healthy hFOB osteoblasts.